<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /data/rsg/nlp/juanmoo1/bin/grobid-0.6.1/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/ rituximab-treated patients: results of a phase 3, randomized, controlled trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marco</forename><surname>Montillo</surname></persName>
							<email>marco.montillo@ospedaleniguarda.it</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution" key="instit1">Niguarda Cancer Center</orgName>
								<orgName type="institution" key="instit2">Niguarda Hospital</orgName>
								<orgName type="institution" key="instit3">Piazza Ospedale Maggiore</orgName>
								<address>
									<postCode>20162</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Árpád</forename><surname>Illés</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution" key="instit1">Niguarda Cancer Center</orgName>
								<orgName type="institution" key="instit2">Niguarda Hospital</orgName>
								<orgName type="institution" key="instit3">Piazza Ospedale Maggiore</orgName>
								<address>
									<postCode>20162</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tadeusz</forename><surname>Robak</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution" key="instit1">Niguarda Cancer Center</orgName>
								<orgName type="institution" key="instit2">Niguarda Hospital</orgName>
								<orgName type="institution" key="instit3">Piazza Ospedale Maggiore</orgName>
								<address>
									<postCode>20162</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alexander</forename><forename type="middle">S</forename><surname>Pristupa</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution" key="instit1">Niguarda Cancer Center</orgName>
								<orgName type="institution" key="instit2">Niguarda Hospital</orgName>
								<orgName type="institution" key="instit3">Piazza Ospedale Maggiore</orgName>
								<address>
									<postCode>20162</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Malgorzata</forename><surname>Wach</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution" key="instit1">Niguarda Cancer Center</orgName>
								<orgName type="institution" key="instit2">Niguarda Hospital</orgName>
								<orgName type="institution" key="instit3">Piazza Ospedale Maggiore</orgName>
								<address>
									<postCode>20162</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Miklós</forename><surname>Egyed</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution" key="instit1">Niguarda Cancer Center</orgName>
								<orgName type="institution" key="instit2">Niguarda Hospital</orgName>
								<orgName type="institution" key="instit3">Piazza Ospedale Maggiore</orgName>
								<address>
									<postCode>20162</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julio</forename><surname>Delgado</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution" key="instit1">Niguarda Cancer Center</orgName>
								<orgName type="institution" key="instit2">Niguarda Hospital</orgName>
								<orgName type="institution" key="instit3">Piazza Ospedale Maggiore</orgName>
								<address>
									<postCode>20162</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wojciech</forename><surname>Jurczak</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution" key="instit1">Niguarda Cancer Center</orgName>
								<orgName type="institution" key="instit2">Niguarda Hospital</orgName>
								<orgName type="institution" key="instit3">Piazza Ospedale Maggiore</orgName>
								<address>
									<postCode>20162</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Franck</forename><surname>Morschhauser</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution" key="instit1">Niguarda Cancer Center</orgName>
								<orgName type="institution" key="instit2">Niguarda Hospital</orgName>
								<orgName type="institution" key="instit3">Piazza Ospedale Maggiore</orgName>
								<address>
									<postCode>20162</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><surname>Schuh</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution" key="instit1">Niguarda Cancer Center</orgName>
								<orgName type="institution" key="instit2">Niguarda Hospital</orgName>
								<orgName type="institution" key="instit3">Piazza Ospedale Maggiore</orgName>
								<address>
									<postCode>20162</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Herbert</forename><surname>Eradat</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution" key="instit1">Niguarda Cancer Center</orgName>
								<orgName type="institution" key="instit2">Niguarda Hospital</orgName>
								<orgName type="institution" key="instit3">Piazza Ospedale Maggiore</orgName>
								<address>
									<postCode>20162</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sanatan</forename><surname>Shreay</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution" key="instit1">Niguarda Cancer Center</orgName>
								<orgName type="institution" key="instit2">Niguarda Hospital</orgName>
								<orgName type="institution" key="instit3">Piazza Ospedale Maggiore</orgName>
								<address>
									<postCode>20162</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jacqueline</forename><forename type="middle">C</forename><surname>Barrientos</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution" key="instit1">Niguarda Cancer Center</orgName>
								<orgName type="institution" key="instit2">Niguarda Hospital</orgName>
								<orgName type="institution" key="instit3">Piazza Ospedale Maggiore</orgName>
								<address>
									<postCode>20162</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">D</forename><surname>Zelenetz</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution" key="instit1">Niguarda Cancer Center</orgName>
								<orgName type="institution" key="instit2">Niguarda Hospital</orgName>
								<orgName type="institution" key="instit3">Piazza Ospedale Maggiore</orgName>
								<address>
									<postCode>20162</postCode>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/ rituximab-treated patients: results of a phase 3, randomized, controlled trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="DOI">10.1186/s12955-019-1232-8</idno>
					<note type="submission">Received: 28 June 2019 Accepted: 11 October 2019</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.1" ident="GROBID" when="2020-10-09T18:38+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Trial registration: Clinicaltrials.gov NCT01569295. Registered April 3</term>
					<term>2012 Idelalisib</term>
					<term>Relapsed/refractory CLL</term>
					<term>Patient-related outcomes</term>
					<term>Health-related quality of life</term>
					<term>Randomized phase 3 study</term>
				</keywords>
			</textClass>
			<abstract>
				<p>Background: In a phase 3 randomized, double-blind, placebo-controlled trial, treatment with idelalisib, a phosphoinositol-3 kinase δ inhibitor, + bendamustine/rituximab improved progression-free survival (PFS) and overall survival (OS) in adult patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Here we report the results of health-related quality of life (HRQL) analyses from this study. Methods: From June 15, 2012 to August 21, 2014, 416 patients with R/R CLL were enrolled; 207 patients were randomized to the idelalisib arm and 209 to the placebo arm. In the 416 patients randomized to receive bendamustine/rituximab and either oral idelalisib 150 mg twice-daily or placebo, HRQL was assessed at baseline and throughout the blinded part of the study using the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) and EuroQoL Five-Dimension (EQ-5D) visual analogue scale (VAS) questionnaires. The assessments were performed at scheduled patient visits; every 4 weeks for the first 6 months from the initiation of treatment, then every 8 weeks for the next 6 months, and every 12 weeks thereafter until end of study. Least-squares mean changes from baseline were estimated using a mixed-effects model by including treatment, time, and treatment-by-time interaction, and stratification factors as fixed effects. Time to first symptom improvement was assessed by Kaplan-Meier analysis. Results: In mixed-effects model analysis, idelalisib + bendamustine/rituximab treatment led to clinically meaningful improvements from baseline in leukemia-associated symptoms. Moreover, per Kaplan-Meier analysis, the proportion of patients with symptom improvement was higher and time to improvement was shorter among patients in the idelalisib-containing arm compared with those who did not receive idelalisib. The physical and social/family FACT-Leu subscale scores, along with the self-rated health assessed by EQ-VAS, showed improvement with idelalisib over placebo, but the difference did not reach statistical significance. The functional and emotional FACT-Leu subscale scores remained similar to placebo. Conclusions: Addition of idelalisib to bendamustine/rituximab, apart from improving PFS and OS, had a neutral to beneficial impact on HRQL in patients with R/R CLL, particularly by reducing leukemia-specific disease symptoms.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p>In 2018, chronic lymphocytic leukemia (CLL)-the most common chronic leukemia-represented an estimated 1.2% of all newly diagnosed cancers in the US, with an estimated 20,940 new CLL cases and 4510 deaths <ref type="bibr" target="#b10">[1]</ref>. The age-adjusted rate of CLL incidence is 4.7 per 100, 000 persons per year. Owing to the introduction of new, improved treatment regimens, the 5-year relative survival rate increased from 65.5% in 1975 to 84.2% in 2014 <ref type="bibr" target="#b10">[1]</ref>. Despite this improvement, CLL remains incurable, and the majority of patients experience disease relapse <ref type="bibr" target="#b11">[2]</ref>. The risk of relapse is increased in patients with CLL-associated genomic aberrations <ref type="bibr">[3]</ref><ref type="bibr" target="#b13">[4]</ref><ref type="bibr" target="#b14">[5]</ref><ref type="bibr" target="#b15">[6]</ref>, patients ≥65 years with comorbid conditions <ref type="bibr" target="#b16">[7]</ref><ref type="bibr" target="#b17">[8]</ref><ref type="bibr" target="#b18">[9]</ref><ref type="bibr" target="#b19">[10]</ref>, and refractory disease <ref type="bibr" target="#b20">[11]</ref>. It is not uncommon for these patients to experience low treatment satisfaction and greatly reduced health-related quality of life (HRQL), mostly due to disease-related symptoms, toxicity of therapies, and anxiety associated with relapsing disease <ref type="bibr" target="#b21">[12]</ref><ref type="bibr" target="#b22">[13]</ref><ref type="bibr" target="#b23">[14]</ref>. Despite recommendations to include prospective analyses of patient-reported outcomes (PROs) as additional endpoints in oncology clinical trials <ref type="bibr" target="#b24">[15]</ref><ref type="bibr" target="#b25">[16]</ref><ref type="bibr" target="#b26">[17]</ref>, PRO-based reports on HRQL in CLL are sparse. Patient-reported outcomes data can provide important information on the impact of new treatment regimens, including their efficacy and toxicity, as seen from the patient's perspective <ref type="bibr" target="#b25">[16]</ref>, and improvement in HRQL often reflects the efficacy of the new treatment under evaluation <ref type="bibr" target="#b27">[18]</ref><ref type="bibr" target="#b28">[19]</ref><ref type="bibr" target="#b29">[20]</ref><ref type="bibr" target="#b30">[21]</ref>.</p><p>Idelalisib, in combination with rituximab, was approved for the treatment of patients with relapsed CLL for whom rituximab alone would be considered an appropriate therapy due to other comorbidities <ref type="bibr" target="#b31">[22]</ref>. To examine the usefulness of idelalisib in additional clinical scenarios, we conducted a pivotal phase 3, randomized, multicenter, double-blind, placebo-controlled trial of idelalisib, a phosphoinositol-3 kinase δ (PI3Kδ) inhibitor, in combination with bendamustine and rituximab, in patients with relapsed/refractory CLL (R/R CLL). The efficacy of the idelalisib/bendamustine/rituximab combination in this trial was superior to placebo/bendamustine/ rituximab, and substantially improved the primary endpoint of progression-free survival (PFS) as well as the key secondary endpoint of overall survival (OS) <ref type="bibr" target="#b32">[23]</ref>.</p><p>Prespecified exploratory endpoints in this study included assessment of HRQL using the Functional Assessment of Cancer Therapy -Leukemia (FACT-Leu) validated questionnaire <ref type="bibr" target="#b33">[24]</ref><ref type="bibr" target="#b34">[25]</ref><ref type="bibr" target="#b35">[26]</ref><ref type="bibr" target="#b36">[27]</ref><ref type="bibr" target="#b37">[28]</ref>. The FACT-Leu was developed as a disease-specific HRQL questionnaire for patients with leukemia <ref type="bibr" target="#b36">[27,</ref><ref type="bibr" target="#b37">28]</ref>, and is composed of subscales scoring the patient's physical, functional, social/ family, and emotional well-being, as well as leukemiaspecific disease symptoms <ref type="bibr" target="#b36">[27,</ref><ref type="bibr" target="#b37">28]</ref>. Another prespecified exploratory endpoint was global health status and selfrated health assessed using the EuroQoL Five-Dimension (EQ-5D) visual analogue scale (VAS) questionnaires <ref type="bibr" target="#b38">[29,</ref><ref type="bibr" target="#b39">30]</ref>. We present the results of these prospectively defined analyses comparing the impact of treatment with idelalisib combined with bendamustine/rituximab with that of bendamustine/rituximab/placebo, on patients' HRQL.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design and participants</head><p>This was a phase 3, randomized, multicenter, doubleblind, placebo-controlled study (NCT01569295) in adult patients who were diagnosed with CLL requiring treatment according to International Workshop on Chronic Lymphocytic Leukemia criteria <ref type="bibr" target="#b26">[17]</ref>. Eligible patients had measurable lymphadenopathy by computed tomography or magnetic resonance imaging, received prior therapy containing a purine analog or bendamustine and an anti-CD20 monoclonal antibody, experienced CLL progression within &lt;36 months since completion of the last prior therapy, were eligible to receive cytotoxic therapy, and had a Karnofsky Performance Status score of ≥60. Study design and detailed eligibility criteria were published previously <ref type="bibr" target="#b32">[23]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics, consent, and permissions</head><p>The study protocols were approved by the Institutional Review Boards at each study site. The trial was conducted according to the principles of Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatments and endpoints</head><p>Patients received oral idelalisib 150 mg or matching placebo twice daily. Bendamustine 70 mg/m 2 was administered intravenously on days 1 and 2 for six 28-day cycles in both arms. Rituximab was administered intravenously with each cycle of bendamustine at 375 mg/m 2 on day 1 of cycle 1, and 500 mg/m 2 on day 1 of cycles 2 to 6. Idelalisib/placebo was given continuously, until disease progression, death, or intolerable toxicity. Bendamustine and rituximab were administered for up to a maximum of 12 and 6 infusions, respectively <ref type="bibr" target="#b32">[23]</ref>.</p><p>The details on primary and secondary endpoints have been reported <ref type="bibr" target="#b32">[23]</ref>. Briefly, the primary endpoint was PFS; OS, overall response rate, and safety were among the key secondary endpoints. The prespecified HRQLrelated exploratory endpoints were change from baseline in HRQL domain and symptom scores based on the FACT-Leu, and change from baseline in overall health and single-item dimension scores from the EQ-5D and EQ-VAS questionnaires. Key time points were the end of the randomized, double-blind initial period of combination therapy with bendamustine/rituximab at week 24 and the end of the preplanned continuing therapy period with idelalisib or placebo alone at week 48.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HRQL assessments</head><p>Patient well-being was assessed using the FACT-Leu questionnaire composed of 44 items measuring physical well-being (PWB, 7 items), functional well-being (FWB, 7 items), social/family well-being (S/FWB, 7 items), emotional well-being (EWB, 6 items), and leukemiaspecific concerns (LeuS, 17 items) <ref type="bibr" target="#b37">[28]</ref>, scored based on the Functional Assessment of Chronic Illness Therapy-3 scoring guideline and user manual <ref type="bibr" target="#b40">[31]</ref>. The subscale scores represent the sums of each individual item score. The composite scores include FACT-Leu total score (range 0-176), which is the sum of all subscales, and the Trial Outcome Index (TOI, range 0-124), which is the sum of the PWB, FWB, and LeuS subscales. Higher scores are associated with better self-reported HRQL.</p><p>The EQ-5D questionnaire contains 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems <ref type="bibr" target="#b41">[32]</ref>. The EQ-5D is converted into a single utility index, designed as an international, standardized questionnaire for evaluation of HRQL <ref type="bibr" target="#b38">[29,</ref><ref type="bibr" target="#b39">30]</ref>, by applying the US preference-weighted index <ref type="bibr" target="#b42">[33]</ref>. The EQ-VAS is used to assess patient's self-rated health on a 100-mm scale ranging from "Worst imaginable health state" to "Best imaginable health state." The EQ-5D utility and EQ-VAS scores are considered reliable and valid for assessing HRQL in cancer patients <ref type="bibr" target="#b43">[34]</ref>. Positive changes from baseline indicate improvement in HRQL.</p><p>The surveys were administered every 4 weeks for the first 6 months from the initiation of treatment, then every 8 weeks for the next 6 months, and every 12 weeks thereafter until the end of study or until the patient was no longer receiving blinded study drug for any reason.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HRQL statistical analyses</head><p>The FACT Leu and EQ-5D questionnaire was scored and processed according to the user manual <ref type="bibr" target="#b41">[32]</ref>. The HRQL questionnaire compliance was defined as a patient having answered at least 1 question at an assessment time point. The compliance rates for each study arm and at each time point were calculated as the number of patients who completed at least 1 question divided by the total number of patients available at that assessment time point. The frequency and proportion of reported problems for each of the five EQ-5D dimensions were summarized at each scheduled assessment. For the FACT-Leu, EQ-VAS questionnaires, and EQ-5D utility index, least-squares mean changes from baseline were estimated using a mixed-effects model, by including treatment, time, and treatment-by-time interaction, and stratification factors as fixed effects. Mixed-effects model used all available data up to week 84, as &lt; 10% of placebo patients have data available beyond week 84. The least-squares means of change from baseline over time were plotted. The minimally important difference (MID) ranges were defined for the different subscales and are summarized in Additional file 1: <ref type="table" target="#tab_0">Table S1</ref>. The lower bound of the MID range was utilized when defining symptom improvement; an increase of at least 3 points from baseline for PWB, S/FWB, FWB, and EWB, and 5 points for LeuS (reaching MID). Time to first symptom improvement was analyzed by the Kaplan-Meier (KM) method. The hazard ratios with 95% confidence intervals (CIs) were estimated from a Cox proportional hazards model without any adjustment and P-value from log-rank test was reported to examine the difference between the 2 treatment arms.</p><p>The HRQL analyses were based on the intent-to-treat analysis set, which included all patients randomized  in the study regardless of whether study drug was administered, and with treatment groups designated according to initial randomization. Nominal P-value threshold of 0.05 was used for significance testing without multiplicity adjustment. All the analyses were performed using SAS version 9.2 (Cary, North Carolina).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Key patient characteristics</head><p>From June 15, 2012, to August 21, 2014, 416 patients with R/R CLL were enrolled; 207 patients were randomized to the idelalisib arm and 209 to the placebo arm. Based on the results of the formal interim analysis performed in June 2015, the Independent Data Monitoring Committee recommended study unblinding. Although the study is still ongoing, the HRQL data presented herein reflect a data cutoff date of October 7, 2015, at the time of study unblinding. At the time of this analysis, 141 (34%) of 416 patients were continuing in the study; 95 (46%) of 207 in the idelalisib group and 46 (22%) of 209 in the placebo group. Patient disposition and demographic and baseline characteristics were published previously <ref type="bibr" target="#b32">[23]</ref>. The patients received a median (quartile [Q1, Q3]) of 6 (4, 6) cycles of treatment with bendamustine and 6 (5, 6) with rituximab; the median (Q1, Q3) exposure to idelalisib and placebo was 14.8 (5.9, 18.9) months and 11.1 <ref type="bibr">(5.8, 15.</ref>3) months, respectively. Generally, demographic and baseline disease characteristics were balanced across the treatment groups <ref type="bibr" target="#b32">[23]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary of the efficacy and safety results</head><p>The detailed efficacy and safety results were previously reported at the data cutoff of October 7, 2015 <ref type="bibr" target="#b32">[23]</ref>, the same as the present analysis. The addition of idelalisib to bendamustine/rituximab led to a substantial improvement in the efficacy of the treatment, compared with bendamustine/rituximab alone <ref type="bibr" target="#b32">[23]</ref>. The most common all-grade adverse events (AEs) were neutropenia and pyrexia in the idelalisib arm and neutropenia and nausea in the placebo arm <ref type="bibr" target="#b32">[23]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient-reported FACT-Leu and EQ-5D outcomes</head><p>Among patients randomized to idelalisib and placebo arms, similar numbers of patients were available for HRQL analyses at baseline <ref type="table" target="#tab_0">(Table 1</ref>). Mean baseline scores for the FACT-Leu and EQ-5D questionnaires were also comparable between the treatment arms ( <ref type="table" target="#tab_0">Table 1)</ref>.</p><p>Assessments of compliance for the FACT-Leu and EQ-5D questionnaires were conducted over the initial (See figure on previous page.) <ref type="figure" target="#fig_0">Fig. 1</ref> Mixed-effects model analysis of FACT-Leu. a, FWB; b, EWB; c, PWB; d, S/FWB; e, LeuS; f, TOI score; g, FACT-Leu total score. Curves above the x-axis indicate positive effects, and curves below the axis show negative effects. Gray area denotes MID range. a P = 0.0525 for treatment difference. b P = 0.0192 for treatment difference. c P = 0.0343 for treatment difference. CI confidence interval, EWB emotional well-being, FACT-Leu Functional Assessment of Cancer Therapy-Leukemia, FWB functional well-being, LeuS leukemia-specific symptoms, MID minimally important difference, PWB physical well-being, S/FWB social/family well-being, TOI trial outcome index  144 weeks of study. Compliance rates for both FACT-Leu and EQ-5D were high and exceeded 80% during the first 120 weeks of study in both treatment arms (Additional file 1: <ref type="table" target="#tab_1">Tables S2 and S3</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>FACT-Leu</head><p>The addition of idelalisib to bendamustine/rituximab had no significant impact on FWB, EWB, and PWB compared with placebo/bendamustine/rituximab <ref type="figure" target="#fig_0">(Fig. 1a,  b, c)</ref>. In contrast, idelalisib increased the S/FWB and LeuS subscale scores, as well as composites TOI and FACT Leu total score, compared with the placebo arm, indicating an improvement in HRQL in idelalisib-treated patients ( <ref type="figure" target="#fig_0">Fig. 1d, e, f, g</ref>). In a mixed-effects model including treatment arm (idelalisib vs placebo) and duration, treatment arm had no significant fixed effect on any FACT-Leu score. The effect of treatment duration was significant for FACT-Leu total score (P = 0.0076), TOI score (P = 0.0103), PWB (P = 0.0017), EWB (P = 0.0142), and LeuS (P = 0.0023); there was no significant interaction between treatment arm and duration for any FACT-Leu score. The treatment difference for idelalisib vs placebo was statistically significant for the LeuS subscale at week 60 (P = 0.0192), and for S/FWB and FACT-Leu total score at week 4 (P = 0.0525 and P = 0.0343, respectively) ( <ref type="figure" target="#fig_0">Fig. 1</ref>, Additional file 1: <ref type="table" target="#tab_3">Table S4</ref>).</p><p>The least squares mean changes from baseline in the LeuS subscale scores were within the MID range of 4 to 7 during the period between week 48 and week 60 in the idelalisib arm, while the values in the placebo arm did not reach the MID at any time points <ref type="figure" target="#fig_0">(Fig. 1e)</ref>. The KM analysis of symptom improvement suggests that an increased number of patients with the MID improvement, as well as shorter time to symptom improvement, were reported for the 5 FACT-Leu subscales in the idelalisib-containing arm compared with the placebo arm, but none of the differences reached statistical significance ( <ref type="table" target="#tab_1">Table 2)</ref>. A higher proportion of patients treated with idelalisib achieved improvement in PWB, S/ FWB and LeuS subscale scores, but not EWB and FWB scores, compared with patients treated with placebo ( <ref type="figure" target="#fig_2">Fig. 2a-e)</ref>. Overall, addition of idelalisib to bendamustine/rituximab had a neutral to numerically favorable effect on change from baseline in FACT-Leu scores of patients with R/R CLL.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>EQ-5D</head><p>Proportions of patients reporting level 1 or 2 EQ-5D health scores at weeks 24 and 48 were generally similar between the idelalisib and placebo treatment arms. Slightly fewer idelalisib-treated patients reported extreme problems (level 3) with anxiety/depression and pain/discomfort at baseline and after 24 and 48 weeks of treatment compared with patients who received placebo ( <ref type="table" target="#tab_2">Table 3</ref>). The EQ-5D utility index and EQ-VAS showed trends toward improvement with idelalisib relative to placebo treatment, but these did not reach significance <ref type="table" target="#tab_3">(Table 4</ref>, <ref type="figure" target="#fig_4">Fig. 3)</ref>. In a mixed-effects model including treatment (idelalisib vs placebo) and treatment duration, treatment duration had a significant fixed effect for EQ-5D utility index (P = 0.0169) and EQ-VAS (P = 0.0061); treatment had no significant fixed effect on either score, but there was a significant fixed effect of the interaction between treatment and treatment duration on EQ-5D utility index (P = 0.0395). Combination therapy with idelalisib vs placebo did not worsen patient-reported  health-and resulted in favorable trends in some measures-in patients with R/R CLL treated with bendamustine/rituximab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>In the primary analysis, the addition of idelalisib to bendamustine/rituximab resulted in superior PFS and OS compared with bendamustine and rituximab alone, thus providing a substantial clinical benefit to R/R CLL patients-a patient population that is difficult to treat <ref type="bibr" target="#b32">[23]</ref>. Apart from treatment goals, a more holistic understanding of the impact of treatment including patients' quality of life is also important, and HRQL data constitutes an important part of treatment evaluation. Because patients in both the idelalisib and placebo arms received concurrent chemo-immunotherapy with associated side effects, idelalisib could not be expected to substantially improve quality of life (QoL) compared with placebo. However, there was potential concern that addition of idelalisib to bendamustine/rituximab would adversely affect change in QoL relative to treatment with bendamustine/rituximab alone. These prospectively defined HRQL analyses indicate that idelalisib in combination with bendamustine/rituximab treatment had a neutral impact on several HRQL domains in patients with R/R CLL compared with bendamustine/rituximab alone. Per mixed-effects model analyses, the addition of idelalisib to bendamustine/rituximab did not affect the FWB and EWB subscale scores, but provided minor improvements in the PWB, S/FWB, and LeuS subscale scores as well as the FACT-Leu composite measures TOI and FACT-Leu total score. Increased LeuS subscale scores in the idelalisib arm were within the MID range at weeks 48 and 60 and reached statistical significance at week 60. The KM analysis of the symptom improvement showed that among idelalisibtreated patients, time to symptom improvement was shortened by approximately 4 to 12 weeks for the LeuS, PWB, and S/FWB subscales, compared with the placebo arm, and a higher proportion of patients had clinically meaningful improvements in these HRQL domains.</p><p>Idelalisib treatment led to small numerical improvements in HRQL in the global health status, as evidenced by the EQ-5D results, particularly reduction of the number of patients who perceived themselves to experience "extreme problems" within the anxiety/depression and pain/discomfort dimensions. The mean changes from baseline in self-rated health, as assessed by EQ-VAS, was also improved, and reached statistical significance vs placebo at week 36 when patients had stopped concurrent chemo-immunotherapy. The rather small differences in overall quality of life observed between the 2 treatment arms may be due to side effects from the concurrent chemo-immunotherapy exerting a dominant effect on quality of life measurements. However, even the slight QoL improvement in patients treated with idelalisib vs placebo in addition to bendamustine/rituximab is valuable information considering the AEs recorded in previous clinical trials of idelalisib <ref type="bibr" target="#b32">[23,</ref><ref type="bibr" target="#b44">35,</ref><ref type="bibr" target="#b45">36]</ref>.</p><p>Recently published analyses of PROs assessed in phase 3 randomized trials in patients with relapsed CLL reported that ibrutinib in combination with bendamustine/rituximab vs bendamustine/rituximab alone neither improved nor adversely impacted HRQL <ref type="bibr" target="#b46">[37]</ref>, and small positive improvements were noted with the addition of ofatumumab to chlorambucil <ref type="bibr" target="#b47">[38]</ref> or to fludarabine and cyclophosphamide <ref type="bibr" target="#b30">[21]</ref>. However, apart from the fact that comparisons of the results across different studies have several limitations, even indirect comparison of these findings with the results from our study is difficult because of different tools used for PRO evaluations (The Functional </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>In summary, in patients with incurable diseases such as CLL, treatment efficacy needs to be balanced with safety and HRQL. In this study, we found that adding idelalisib to bendamustine/rituximab-even for those patients already treated with a prior bendamustine-containing regimen-improved treatment efficacy with, importantly, a neutral or beneficial impact on patients' HRQL. These HRQL findings provide additional information to balance the improved efficacy of the combination regimen with possible safety concerns reported with idelalisib use <ref type="bibr" target="#b32">[23]</ref>. Overall, these results further support the existing body of evidence indicating that idelalisib treatment benefits patients with R/R CLL. </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 (</head><label>1</label><figDesc>Analyzed in the ITT population. All data presented as mean (SD); n indicates number of patients available for HRQL assessment at baseline EQ-5D EuroQoL Five-Dimension, FACT-Leu functional assessment of cancer therapy-leukemia, EWB emotional well-being, FWB functional well-being, HRQL healthrelated quality of life, ITT intent-to-treat, LeuS leukemia-specific concerns, PWB physical well-being, S/FWB social/family well-being, SD standard deviation, TOI trial outcome index, VAS visual analog scalea FACT-Leu Total = LeuS + PWB + S/FWB + EWB + FWB b TOI = LeuS + PWB + FWB See legend on next page.)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>7 c</head><label>7</label><figDesc>Analyzed in the ITT population. Patients with baseline PWB/S/FWB/FWB &gt; 25, EWB &gt; 21, and LeuS &gt; 63 are not included in the respective analysis of improvement CI confidence interval, EWB emotional well-being, FWB functional well-being, HRQL health-related quality of life, HR hazard ratio, ITT intent-to-treat, LeuS leukemiaspecific concerns, MID minimally important difference, PWB physical well-being, S/FWB social/family well-being a Data presented as n (%). MID symptom improvement was defined as an increase of ≥3 points from baseline for PWB/S/FWB/FWB/EWB and 5 points for LeuS b Data presented as median (95% CI), weeks. Patients who did not experience a symptom improvement compared to baseline were censored at their last available HRQL assessment time. Time to symptom improvement (weeks) = (date of first symptom improvement − date of randomization + 1)/Data presented as n (%). Patients with any increase from baseline</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 2</head><label>2</label><figDesc>Percent of patients with improvements in FACT-Leu subscales (Kaplan-Meier analysis). a, PWB; b, S/FWB; c, LeuS; d, EWB; e, FWB. EWB emotional well-being, FACT-Leu Functional Assessment of Cancer Therapy-Leukemia, FWB functional well-being, LeuS leukemia-specific symptoms, PWB physical well-being, S/FWB social/family well-being</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>9 )</head><label>9</label><figDesc>Analyzed in the ITT population. All data represented as n (%) Level 1: no problems; Level 2: some problems; Level 3: extreme problems EQ-5D EuroQoL Five-Dimension, ITT intent-to-treat</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig. 3</head><label>3</label><figDesc>Mixed-effects model analysis of EuroQoL Five-Dimension VAS. CI confidence interval, VAS visual analogue scale</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc>Scores for the HRQL questionnaires at baseline</figDesc><table><row><cell></cell><cell>Idelalisib/rituximab/bendamustine, N = 207</cell><cell>n</cell><cell>Placebo/rituximab/bendamustine, N = 209</cell><cell>n</cell></row><row><cell>FACT-Leu total score a</cell><cell>125.27 (24.103)</cell><cell>196</cell><cell>123.17 (27.540)</cell><cell>202</cell></row><row><cell>Trial outcome index score b</cell><cell>86.12 (18.662)</cell><cell>196</cell><cell>84.71 (21.337)</cell><cell>203</cell></row><row><cell>Physical well-being</cell><cell>21.77 (5.012)</cell><cell>197</cell><cell>21.39 (5.418)</cell><cell>203</cell></row><row><cell>Social/family well-being</cell><cell>21.51 (5.502)</cell><cell>198</cell><cell>21.40 (5.392)</cell><cell>203</cell></row><row><cell>Emotional well-being</cell><cell>17.68 (4.215)</cell><cell>198</cell><cell>16.93 (4.902)</cell><cell>204</cell></row><row><cell>Functional well-being</cell><cell>17.99 (6.068)</cell><cell>199</cell><cell>17.32 (6.135)</cell><cell>204</cell></row><row><cell>Leukemia-specific symptoms</cell><cell>46.31 (10.312)</cell><cell>199</cell><cell>45.95 (12.206)</cell><cell>204</cell></row><row><cell>EQ-5D utility index</cell><cell>0.78 (0.217)</cell><cell>197</cell><cell>0.78 (0.228)</cell><cell>195</cell></row><row><cell>EQ-VAS</cell><cell>68.8 (17.81)</cell><cell>190</cell><cell>67.4 (19.28)</cell><cell>194</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc>Summary of symptom improvement</figDesc><table><row><cell></cell><cell cols="3">Idelalisib/bendamustine/rituximab, N = 207</cell><cell cols="3">Placebo/bendamustine/rituximab, N = 209</cell><cell></cell></row><row><cell></cell><cell>Patients with</cell><cell>Time to</cell><cell>Proportion of patients</cell><cell>Patients with</cell><cell>Time to</cell><cell>Proportion of patients</cell><cell>HR</cell><cell>P-value</cell></row><row><cell></cell><cell>MID</cell><cell>symptom</cell><cell>with any symptom</cell><cell>MID</cell><cell>symptom</cell><cell>with any symptom</cell><cell>(95% CI)</cell></row><row><cell></cell><cell>improvement a</cell><cell>improvement b</cell><cell>improvement c</cell><cell>improvement a</cell><cell>improvement b</cell><cell>improvement c</cell><cell></cell></row><row><cell>PWB</cell><cell>97 (69.3)</cell><cell>12.3 (9.1, 16.1)</cell><cell>139 (67.1)</cell><cell>89 (61.8)</cell><cell>20.9 (12.9, 30.1)</cell><cell>141 (67.5)</cell><cell cols="2">1.28 (0.96, 1.70) 0.1026</cell></row><row><cell></cell><cell></cell><cell>N = 140</cell><cell></cell><cell></cell><cell>N = 144</cell><cell></cell><cell></cell></row><row><cell cols="2">S/FWB 82 (59.0)</cell><cell>20.4 (12.1, 39.9)</cell><cell>130 (62.8)</cell><cell>79 (52.7)</cell><cell>32.4 (16.3, 72.7)</cell><cell>139 (66.5)</cell><cell cols="2">1.20 (0.88, 1.63) 0.2663</cell></row><row><cell></cell><cell></cell><cell>N = 139</cell><cell></cell><cell></cell><cell>N = 150</cell><cell></cell><cell></cell></row><row><cell>EWB</cell><cell>99 (62.7)</cell><cell>16.1 (8.9, 23.9)</cell><cell>159 (76.8)</cell><cell>103 (61.7)</cell><cell>16.9 (12.4, 24.4)</cell><cell>147 (70.3)</cell><cell cols="2">1.04 (0.79, 1.37) 0.8357</cell></row><row><cell></cell><cell></cell><cell>N = 158</cell><cell></cell><cell></cell><cell>N = 167</cell><cell></cell><cell></cell></row><row><cell>FWB</cell><cell>102 (60.0)</cell><cell>20.9 (12.1, 39.9)</cell><cell>142 (68.6)</cell><cell>100 (55.2)</cell><cell>24.7 (16.1, 44.3)</cell><cell>145 (69.4)</cell><cell cols="2">1.07 (0.81, 1.42) 0.6321</cell></row><row><cell></cell><cell></cell><cell>N = 170</cell><cell></cell><cell></cell><cell>N = 181</cell><cell></cell><cell></cell></row><row><cell cols="2">LeuS 142 (74.7)</cell><cell>8.4 (6.3, 12.7)</cell><cell>168 (81.2)</cell><cell>133 (68.6)</cell><cell>12.3 (11, 16.3)</cell><cell>168 (80.4)</cell><cell cols="2">1.22 (0.96, 1.55) 0.1134</cell></row><row><cell></cell><cell></cell><cell>N = 190</cell><cell></cell><cell></cell><cell>N = 194</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc>Summary of EQ-5D questionnaire by dimensionIdelalisib/rituximab/bendamustine, N = 207Placebo/rituximab/bendamustine, N = 209</figDesc><table><row><cell>Dimensions</cell><cell>Baseline</cell><cell>Week 24</cell><cell>Week 48</cell><cell>Baseline</cell><cell>Week 24</cell><cell>Week 48</cell></row><row><cell>Anxiety/Depression</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Level 1</cell><cell>113 (57.1)</cell><cell>102 (65.8)</cell><cell>85 (66.4)</cell><cell>117 (59.1)</cell><cell>91 (60.3)</cell><cell>70 (66.7)</cell></row><row><cell>Level 2</cell><cell>84 (42.4)</cell><cell>50 (32.3)</cell><cell>41 (32.0)</cell><cell>75 (37.9)</cell><cell>55 (36.4)</cell><cell>32 (30.5)</cell></row><row><cell>Level 3</cell><cell>1 (0.5)</cell><cell>3 (1.9)</cell><cell>2 (1.6)</cell><cell>6 (3.0)</cell><cell>5 (3.3)</cell><cell>3 (2.9)</cell></row><row><cell>Mobility</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Level 1</cell><cell>145 (73.6)</cell><cell>119 (76.8)</cell><cell>94 (73.4)</cell><cell>142 (71.4)</cell><cell>112 (74.7)</cell><cell>84 (80.0)</cell></row><row><cell>Level 2</cell><cell>52 (26.4)</cell><cell>36 (23.2)</cell><cell>34 (26.6)</cell><cell>55 (27.6)</cell><cell>38 (25.3)</cell><cell>21 (20.0)</cell></row><row><cell>Level 3</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>2 (1.0)</cell><cell>0</cell><cell>0</cell></row><row><cell>Pain/Discomfort</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Level 1</cell><cell>105 (53.3)</cell><cell>96 (61.9)</cell><cell>77 (60.2)</cell><cell>114 (57.0)</cell><cell>79 (52.3)</cell><cell>63 (60.6)</cell></row><row><cell>Level 2</cell><cell>85 (43.1)</cell><cell>54 (34.8)</cell><cell>51 (39.8)</cell><cell>81 (40.5)</cell><cell>69 (45.7)</cell><cell>37 (35.6)</cell></row><row><cell>Level 3</cell><cell>7 (3.6)</cell><cell>5 (3.2)</cell><cell>0</cell><cell>5 (2.5)</cell><cell>3 (2.0)</cell><cell>4 (3.8)</cell></row><row><cell>Self-Care</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Level 1</cell><cell>184 (92.9)</cell><cell>136 (87.7)</cell><cell>115 (89.8)</cell><cell>184 (92.5)</cell><cell>131 (86.8)</cell><cell>92 (87.6)</cell></row><row><cell>Level 2</cell><cell>14 (7.1)</cell><cell>19 (12.3)</cell><cell>13 (10.2)</cell><cell>13 (6.5)</cell><cell>20 (13.2)</cell><cell>12 (11.4)</cell></row><row><cell>Level 3</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>2 (1.0)</cell><cell>0</cell><cell>1 (1.0)</cell></row><row><cell>Usual Activities</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Level 1</cell><cell>126 (63.6)</cell><cell>93 (60.4)</cell><cell>83 (64.8)</cell><cell>122 (61.3)</cell><cell>87 (57.6)</cell><cell>71 (68.3)</cell></row><row><cell>Level 2</cell><cell>65 (32.8)</cell><cell>52 (33.8)</cell><cell>45 (35.2)</cell><cell>70 (35.2)</cell><cell>61 (40.4)</cell><cell>31 (29.8)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4</head><label>4</label><figDesc>Mixed-effects model analysis for functional assessment of cancer therapy using EQ-5D in the ITT population CI confidence interval, EQ-5D EuroQoL Five-Dimension, UI utility index, ITT intent-to-treat, LSM least squares means, VAS visual analog scale Assessment of Chronic Illness Therapy -Fatigue scale and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, in the ibrutinib and ofatumumab studies, and FACT-Leu in this study).</figDesc><table><row><cell cols="2">Treatment difference a LSM (95% CI)</cell><cell></cell></row><row><cell></cell><cell>EQ-5D UI</cell><cell>EQ-VAS</cell></row><row><cell>Week 4</cell><cell>0.03 (−0.01, 0.07)</cell><cell>0.18 (−3.24, 3.61)</cell></row><row><cell>P-value</cell><cell>0.1302</cell><cell>0.9167</cell></row><row><cell>Week 8</cell><cell>−0.01 (−0.05, 0.04)</cell><cell>−1.54 (−5.06, 1.98)</cell></row><row><cell>P-value</cell><cell>0.7570</cell><cell>0.3895</cell></row><row><cell>Week 12</cell><cell>0.00 (−0.04, 0.05)</cell><cell>−1.00 (−4.96, 2.97)</cell></row><row><cell>P-value</cell><cell>0.8730</cell><cell>0.6216</cell></row><row><cell>Week 16</cell><cell>0.02 (−0.03, 0.07)</cell><cell>−0.09 (−3.82, 3.65)</cell></row><row><cell>P-value</cell><cell>0.4325</cell><cell>0.9631</cell></row><row><cell>Week 20</cell><cell>0.02 (−0.03, 0.06)</cell><cell>0.17 (−3.74, 4.09)</cell></row><row><cell>P-value</cell><cell>0.4514</cell><cell>0.9301</cell></row><row><cell>Week 24</cell><cell>0.04 (−0.01, 0.08)</cell><cell>−0.04 (−3.92, 3.85)</cell></row><row><cell>P-value</cell><cell>0.1433</cell><cell>0.9851</cell></row><row><cell>Week 30</cell><cell>0.03 (−0.02, 0.08)</cell><cell>0.69 (−3.36, 4.73)</cell></row><row><cell>P-value</cell><cell>0.2915</cell><cell>0.7389</cell></row><row><cell>Week 36</cell><cell>0.02 (−0.03, 0.07)</cell><cell>1.94 (−2.24, 6.13)</cell></row><row><cell>P-value</cell><cell>0.4630</cell><cell>0.3623</cell></row><row><cell>Week 42</cell><cell>0.00 (−0.06, 0.06)</cell><cell>−1.56 (−5.92, 2.80)</cell></row><row><cell>P-value</cell><cell>0.9995</cell><cell>0.4823</cell></row><row><cell>Week 48</cell><cell>0.02 (−0.04, 0.07)</cell><cell>1.99 (−2.06, 6.03)</cell></row><row><cell>P-value</cell><cell>0.5601</cell><cell>0.3348</cell></row><row><cell>Week 60</cell><cell>0.03 (−0.03, 0.09)</cell><cell>1.53 (−3.05, 6.11)</cell></row><row><cell>P-value</cell><cell>0.2981</cell><cell>0.5128</cell></row><row><cell>Week 72</cell><cell>0.04 (−0.04, 0.11)</cell><cell>−0.97 (−6.41, 4.48)</cell></row><row><cell>P-value</cell><cell>0.3131</cell><cell>0.7275</cell></row><row><cell>Week 84</cell><cell>−0.04 (− 0.11, 0.02)</cell><cell>0.03 (−6.14, 6.20)</cell></row><row><cell>P-value</cell><cell>0.2039</cell><cell>0.9921</cell></row></table><note></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p>This study was sponsored by Gilead Sciences, Inc. (Foster City, CA; and Seattle, WA). The authors would like to thank Henry Adewoye and Yeonhee Kim, former employees of Gilead Sciences, Inc., for their invaluable input on the early drafts of this manuscript. Medical writing and editorial support were provided by Ewa Wandzioch, PhD; and Meryl Gersh, PhD, of AlphaBioCom, LLC, King of Prussia, PA, and was funded by Gilead Sciences, Inc.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary information</head><p>Supplementary information accompanies this paper at https://doi.org/10. 1186/s12955-019-1232-8.</p><p>Additional file 1: <ref type="table">Table S1</ref>. Questionnaires used to assess healthrelated quality of life. <ref type="table">Table S2</ref>. Compliance rates: FACT-Leu questionnaire. <ref type="table">Table S3</ref>. Compliance rates: EQ-5D questionnaire. <ref type="table">Table S4</ref>. Mixed-effects model analysis estimates (idelalisib/placebo) for functional assessment of cancer therapy using FACT-Leu. Authors' contributions All authors made substantial contributions to the acquisition, analysis, and/or interpretation of the data, provided critical feedback on manuscript content, provided final approval for submission of the manuscript to this journal, and have agreed to be accountable for all aspects of the work.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p>This study was funded by Gilead Sciences, Inc.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Availability of data and materials</head><p>The data that support the findings of this study are available from Gilead Sciences, Inc., but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Gilead Sciences, Inc.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics approval and consent to participate</head><p>The study protocols were approved by the Institutional Review Boards at each study site. The trial was conducted according to the principles of Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent.</p><p>Competing interests MM reports research grants, personal fees, and nonfinancial support from Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m">Gilead Sciences, Inc.; as well as personal fees from Janssen, Roche, and Novartis. AI, ASP, ME, and WJ report institutional research grants from Gilead Sciences, Inc. TR reports research support and personal fees from Gilead Sciences, Inc. MW reports nothing to disclose. JD reports consulting and lecturing fees from Gilead Sciences, Inc.; Janssen; Roche; and GSK-Novartis. FM reports personal fees from Celgene</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Genentech/Roche; Gilead</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Sciences</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">.</forename><forename type="middle">;</forename><surname>Inc</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Janssen</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AS reports honoraria from AbbVie</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m">Gilead Sciences, Inc.; Janssen; and Roche; and nonrestricted educational grants from Gilead Sciences, Inc.; and Janssen. HE reports honoraria from Gilead Sciences, Inc.; AbbVie; Genentech; Pharmacyclics; and Janssen; consulting or advisory roles with Gilead Sciences, Inc.; AbbVie; Genentech; Pharmacyclics; and Janssen</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Gilead Sciences, Inc.; AbbVie; Genentech</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m">Pharmacyclics; and Takeda; and research funding from Gilead Sciences, Inc.; AbbVie; Genentech; Pharmacyclics; Roche; Celgene; Novartis; Kite; GlaxoS-mithKline; AstraZeneca; ATARA; BeiGene; TG Therapeutics; and Verastem. SS is an employee of Gilead Sciences, Inc.; and may hold stock. JCB reports consulting or advisory roles with Pharmacyclics/AbbVie; Janssen; Genentech</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
	</analytic>
	<monogr>
		<title level="m">and Gilead Sciences, Inc.; honoraria from Janssen; and institutional research funding from Pharmacyclics/AbbVie and Gilead Sciences</title>
		<imprint>
			<publisher>Janssen</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m">Amgen; Novartis; and Adaptive Biotech; consulting or advisory roles with Genentech/Roche; Gilead Sciences, Inc.; Celgene; Janssen; Amgen; Novartis</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m">Adaptive Biotechnologies; and MEI Pharma; research funding from MEI Pharma</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">/</forename><surname>Genentech</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Roche</surname></persName>
		</author>
		<title level="m">Gilead Sciences, Inc.; BeiGene; and AbbVie; travel, accommodations, and expenses paid by Roche; Gilead Sciences, Inc.; and Celgene</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, UK. 11 Division of Hematology-Oncology</title>
	</analytic>
	<monogr>
		<title level="j">David Geffen School of Medicine at UCLA</title>
		<imprint>
			<biblScope unit="issue">7</biblScope>
			<publisher>12 Gilead Sciences, Inc</publisher>
		</imprint>
		<respStmt>
			<orgName>Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland. 4 Department of Hematology, Ryazan Regional Clinical Hospital, Ryazan, Russia. 5 Department Hemato-Oncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland. 6 Department of Hematology, Somogy County Kaposi Mor Hospital ; Department of Hematology, Université de Lille</orgName>
		</respStmt>
	</monogr>
	<note>13 Zucker School of Medicine at Hofstra/Northwell. 14 Memorial Sloan Kettering Cancer Center</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<ptr target="https://seer.cancer.gov/statfacts/html/clyl.html" />
	</analytic>
	<monogr>
		<title level="m">SEER Cancer statistics review</title>
		<imprint>
			<date type="published" when="1975" />
			<biblScope unit="volume">22</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. NCCN Clinical Practice Guidelines in</title>
	</analytic>
	<monogr>
		<title level="j">Oncology</title>
		<imprint>
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">What is the best frontline therapy for patients with CLL and 17p deletion?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><forename type="middle">C</forename><surname>Badoux</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Keating</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">G</forename><surname>Wierda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Hematol Malig Rep</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="36" to="46" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Dicker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Herholz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Schnittger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Nakao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Patten</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="117" to="141" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Genomic aberrations and survival in chronic lymphocytic leukemia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Dohner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Stilgenbauer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Benner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Leupolt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Krober</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Bullinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="page" from="1910" to="1916" />
			<date type="published" when="2000" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Stilgenbauer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Sander</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Bullinger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Benner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Leupolt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Winkler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="1242" to="1247" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Shanafelt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hematol Am Soc Hematol Educ Program</title>
		<imprint>
			<biblScope unit="volume">2013</biblScope>
			<biblScope unit="page" from="158" to="67" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">How I treat elderly or comorbid patients with chronic lymphocytic leukemia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Smolej</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Med (Hradec Kralove)</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="213" to="233" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Therapy of elderly/comorbid patients with chronic lymphocytic leukemia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Smolej</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Pharm Des</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="3399" to="405" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<title level="m" type="main">National Cancer Institute: Surveillance Epidemiology and End Results (SEER) program. SEER Stat Fact Sheets: Chronic Lymphocytic Leukemia</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Treatment of relapsed or refractory chronic lymphocytic leukemia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Veliz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Pinilla-Ibarz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Control</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="37" to="53" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">D</forename><surname>Shanafelt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Bowen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Venkat</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">L</forename><surname>Slager</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">S</forename><surname>Zent</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">E</forename><surname>Kay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="255" to="64" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">M</forename><surname>Holtzer-Goor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">R</forename><surname>Schaafsma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Joosten</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">F</forename><surname>Posthuma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Wittebol</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">C</forename><surname>Huijgens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="2895" to="906" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Quality of life in chronic lymphocytic leukemia: a neglected issue</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Molica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="1709" to="1723" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Basch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">P</forename><surname>Abernethy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">D</forename><surname>Mullins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">B</forename><surname>Reeve</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Coons</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="4249" to="55" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Standardizing patient-reported outcomes assessment in cancer clinical trials: a patientreported outcomes measurement information system initiative</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">F</forename><surname>Garcia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Cella</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">B</forename><surname>Clauser</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">E</forename><surname>Flynn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Lad</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">S</forename><surname>Lai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="5106" to="5118" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Hallek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">D</forename><surname>Cheson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Catovsky</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Caligaris-Cappio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Dighiero</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Dohner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="5446" to="56" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Healthrelated quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: what have we learned?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Cannella</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Caocci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Vignetti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Mandelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Efficace</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Rev Oncol Hematol</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="542" to="54" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Catovsky</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Richards</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Matutes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Oscier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Dyer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">F</forename><surname>Bezares</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="page" from="230" to="239" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">F</forename><surname>Eichhorst</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Busch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Obwandner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Kuhn-Hallek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Herschbach</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Hallek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">German Cll Study</forename><surname>Group</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1722" to="1753" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Robak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Warzocha</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Govind</forename><surname>Babu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Kulyaba</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Kuliczkowski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Abdulkadyrov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1598" to="606" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title level="m" type="main">ZYDELIG® (idelalisib) Prescribing Information</title>
		<ptr target="http://www.gilead.com/~/media/Files/pdfs/medicines/oncology/zydelig/zydelig_pi.pdf" />
		<imprint>
			<date type="published" when="2016" />
			<publisher>Gilead Sciences, Inc</publisher>
			<pubPlace>Foster City, CA, USA</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">D</forename><surname>Zelenetz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">C</forename><surname>Barrientos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Coiffier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Delgado</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Egyed</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="297" to="311" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">S</forename><surname>Brucker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Yost</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Cashy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Webster</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Cella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eval Health Prof</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="192" to="211" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">The Functional Assessment of Cancer Therapy scale: development and validation of the general measure</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">F</forename><surname>Cella</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">S</forename><surname>Tulsky</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Sarafian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Linn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Bonomi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="570" to="579" />
			<date type="published" when="1993" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Reliability across studies from the Functional Assessment of Cancer Therapy-General (FACT-G) and its subscales: a reliability generalization</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Victorson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Barocas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Cella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1137" to="1183" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Measuring quality of life (QOL) among patients with leukemia: the Functional Assessment of Cancer Therapy-Leukemia (FACT-LEU)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Webster</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Chivington</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Shonk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Eremenco</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Yount</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Hahn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<date type="published" when="2002" />
		</imprint>
	</monogr>
	<note>Abstract 678</note>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title level="m" type="main">Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy -Leukemia (FACT-Leu) questionnaire. Value Health</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Cella</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">E</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Webster</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Hongyan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">S</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Rosen</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2012" />
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1051" to="1059" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<monogr>
		<title level="m" type="main">EuroQol-a new facility for the measurement of health-related quality of life. Health Policy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Euroqol</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1990" />
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="199" to="208" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">EQ-5D: a measure of health status from the EuroQol group</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Rabin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>De Charro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Med</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="337" to="380" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Facit</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Org</surname></persName>
		</author>
		<ptr target="http://www.facit.org/FACITOrg/Questionnaires.Accessed09" />
		<imprint>
			<date type="published" when="2015-03" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<monogr>
		<title level="m" type="main">Basic information on how to use the EQ-5D-5L instrument version 2.1</title>
		<ptr target="https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-5L_UserGuide_2015.pdf.2015" />
		<editor>EuroQol Research Foundation. EQ-5D-5L User Guide</editor>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">US valuation of the EQ-5D health states: development and testing of the D1 valuation model</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Shaw</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Coons</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Care</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="203" to="223" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">S</forename><surname>Pickard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">P</forename><surname>Neary</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Cella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Health Qual Life Outcomes</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">70</biblScope>
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Idelalisib and rituximab in relapsed chronic lymphocytic leukemia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">R</forename><surname>Furman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">P</forename><surname>Sharman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">E</forename><surname>Coutre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">D</forename><surname>Cheson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Pagel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Hillmen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="page" from="997" to="1007" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Robak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">T</forename><surname>Awan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Badoux</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Coutre</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Haematol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="114" to="140" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Cramer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Fraser</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Santucci-Silva</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Grosicki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Dilhuydy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Janssens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="2075" to="84" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Hillmen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Janssens</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">G</forename><surname>Babu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Kloczko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Grosicki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Manson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Oncol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1115" to="1135" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
